Evidence map›Paper›PMID 10947081›Full record

ArticleGene expression1999

Metastatic conversion of chemically transformed human cells.

X L Sun, D Li, J Fang, B Casto, I Noyes, G E Milo

Open access · greenAbstract read
In one paragraph

Article in Gene expression, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

X L SunDepartment of Medical Biochemistry and Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus 43210, USA. sun.73@osu.edu
D Li
J Fang
B Casto
I Noyes
G E Milo
The Ohio State University · US

Funding

TGF BETA RECEPTOR COMPLEX IN ORAL CANCER DEVELOPMENTP01DE012704 · NIDCR · OHIO STATE UNIVERSITY · PI STONER, GARY D · 1998 to 2002
$3.0M
High-mobility group box-1 and alcoholic liver diseaseR01AA025907 · NIAAA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NIETO, NATALIA · 2018 to 2022
$1.8M
NEOPLASTIC TRANSFORMATION OF HUMAN EPITHELIAL CELLSR01CA025907 · NCI · OHIO STATE UNIVERSITY · PI MILO, GEORGE E · 1985 to 1996
–
NCI NIH HHS R01 CA25907-12NIAAA NIH HHS R01 AA025907NIDCR NIH HHS 1P01 DE 12704NIDCR NIH HHS P01 DE012704
6 · The paper itself

Abstract

A linear model for human cell metastasis has been developed in vitro from chemically transformed normal human cells. The chemically transformed cells are nontumorigenic in nude mice, but can be converted to a tumorigenic phenotype by transfection with a nondirectional cDNA library or antisense cDNA to the ML-1 gene. The primary transfected cell line (TR1T) forms localized, progressively growing tumors in nude mice that do not invade into the surrounding tissue. This tumorigenic TR1T cell line could be advanced into a metastatic stage following an additional transfection (TR2M cell line) with the cDNA expression library or antisense cDNA to the ML-1 gene. Metastatic cells, selected from tumors that were attached to internal organs, exhibited an increase in invasiveness as measured in vitro using an invasion chamber. The metastatic cells also exhibited an increased expression of matrix metalloproteinase-1 (MMP-1), although MMP-1 was not part of the cDNA that was transfected into either the TR1T cells or the doubly transfected metastatic TR2M cells. These data suggest that the increase in MMP-1 expression was a secondary downstream event responding to an upstream genetic change that initiated the conversion of cells from a tumorigenic to a metastatic stage. In summary, human cell lines representing premalignant, malignant, and metastatic phenotypes have been established in culture that can be used to identify gene changes that occur as normal human cells progress to a metastatic stage during tumor development. One gene, ML-1, that is found in the expression library appears to be involved in malignant progression, because ML-1 antisense cDNA will convert chemically transformed cells to both tumorigenic and metastatic stages, and cells from both local and metastatic tumors have a reduced or complete loss of expression of the ML-1 gene.

Indexed as

AnimalsCarcinogenicity TestsCell Line, TransformedCell Transformation, NeoplasticDNA, AntisenseGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMaleMatrix Metalloproteinase 1MiceMice, NudeNeoplasm MetastasisNeoplasms, ExperimentalTissue Inhibitor of Metalloproteinase-1DNA, AntisenseMatrix Metalloproteinase 1Tissue Inhibitor of Metalloproteinase-1

Identifiers

PMID10947081
PMCPMC6157377
OpenAlexW2474570565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.